Corcept Therapeutics Incorporated (CORT)
收市後：
Corcept Therapeutics Incorporated
149 Commonwealth Drive
Menlo Park, CA 94025
United States
650 327 3270
https://www.corcept.com
版塊: Healthcare
行業: Biotechnology
全職員工: 352
高階主管
| 名稱 | 頭銜 | 支付 | 行使價 | 出生年份 |
|---|---|---|---|---|
| Dr. Joseph K. Belanoff M.D. | Co-Founder, President, CEO & Director | 2.43M | 無 | 1957 |
| Mr. Atabak Mokari | CFO & Treasurer | 863.03k | 無 | 1977 |
| Mr. Sean Maduck | President of Endocrinology | 1.05M | 2.7M | 1977 |
| Dr. William Guyer Pharm.D. | Chief Development Officer | 1.03M | 135k | 1968 |
| Mr. Gary Charles Robb | Chief Business Officer & Secretary | 1.08M | 3.01M | 1963 |
| Mr. Joseph Douglas Lyon | Chief Accounting & Technology Officer | 無 | 無 | 1978 |
| Dr. Hazel Hunt Ph.D. | Chief Scientific Officer | 895.16k | 1.75M | 1960 |
| Ms. Amy Flood | Chief Human Resources & Communications Officer | 無 | 無 | 無 |
| Ms. Monica Tellado | President of Emerging Markets | 無 | 無 | 1973 |
| Mr. Roberto W. Vieira | President of Oncology | 無 | 無 | 無 |
描述
Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. The company is also developing relacorilant, which is in phase III clinical trial for the treatment of cushing's syndrome; treatment for adrenal cancer and cortisol excess which is in phase 1b clinical trial; treatment for prostate cancer which is in phase II clinical trial; and nab-paclitaxel in combination with relacorilant, which is in phase III clinical trial to treat platinum-resistant ovarian tumors. In addition, it develops dazucorilant, which is in phase II clinical trial for the treatment of amyotrophic lateral sclerosis; miricorilant, which is in phase IIb trial for the treatment of nonalcoholic steatohepatitis; and treatment for antipsychotic induced weight gain that is in phase I trial. The company was incorporated in 1998 and is headquartered in Menlo Park, California.
公司管治
截至 2024年5月1日 止，Corcept Therapeutics Incorporated 的 ISS 管治質素評分為 5。 Pillar 分數正在審核中：4；董事會：4；股東權利：6；現金賠償：7。
